IMB is a privately held, late stage medical device company. IMB’s focus is to commercialize novel products to be used in the treatment of solid malignant and benign vascularized tumors and hypertrophic/hyperplastic tissue. The company’s core technology has been developed for the treatment of vascularized cancer tumors, uterine fibroids, and benign prostatic hyperplasia (BPH).
Our lead product, Ekobi® Embolization Microspheres is commercially available in Canada and the USA. It is a biodegradable embolic agent that is detectable by ultrasound. IMB’s unique product gives doctors and patients a safe and effective alternative to surgery. Embolization is a rapidly growing market and Ekobi Embolization Microspheres is the only biodegradable embolic agent that is visible by ultrasound.
For more information on investor participation, please contact us.